secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2023-10-23T23:59:59+00:00
Accession:  0001193125-23-260795
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC-114 Phase 1 data shows first confirmed CNS complete response in EGFR exon 20 NSCLC
--------------------------------------------------------------------------------

- 81% of EGFR exon 20 NSCLC patients had prior exon 20 targeted agents; 86% had CNS metastases at baseline.
- At 75 mg QD (potential RP2D): 67% unconfirmed ORR and 33% confirmed ORR in post-amivantamab patients (n=3).
- First confirmed CNS complete response reported by an EGFR exon 20 inhibitor in untreated brain metastases.
- HER2 exon 20 patients: partial responses observed, including 100% target lesion regression.
- Favorable safety: mostly Grade 1-2 TRAEs; no Grade 3+ rash; 4% discontinuations; MTD not reached.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312523260795/0001193125-23-260795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312523260795/d561418d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-260795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer